Syndax Pharmaceuticals, Inc.
SNDX
$11.54
$0.494.43%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -318.76M | -297.06M | -264.08M | -240.63M | -209.36M |
| Total Depreciation and Amortization | 8.00K | 11.00K | 12.00K | 12.00K | 12.00K |
| Total Amortization of Deferred Charges | 30.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.55M | 26.09M | 21.82M | 19.83M | 16.89M |
| Change in Net Operating Assets | 13.27M | 12.09M | 1.05M | 15.87M | 31.86M |
| Cash from Operations | -274.90M | -258.86M | -241.20M | -204.92M | -160.60M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -219.78M | 32.91M | -13.86M | -1.71M | 117.61M |
| Cash from Investing | -219.78M | 32.91M | -13.86M | -1.71M | 117.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.72M | 264.43M | 263.18M | 263.83M | 264.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 343.65M | -- | -- | -- | -- |
| Cash from Financing | 353.37M | 264.43M | 263.18M | 263.83M | 264.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -141.31M | 38.47M | 8.12M | 57.20M | 221.14M |